NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction & Lenalidomide Maint

NCT04786028: Phase 2 - A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

This is a phase II multi-center, open label, single arm study to evaluate the safety and efficacy of Isatuximab administered intravenously in combination with CyBorD induction treatment and Lenalidomide maintenance treatment in a 28-day long cycle in autologous stem cell transplant-eligible patients.

Sponsor

Canadian Myeloma Research Group

Location

Canada

---

ClinicalTrials.gov Identifier: NCT04786028

Official Title: A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma

First Posted: March 8, 2021

Click here to see details on ClinicalTrials.gov

---

Isatuximab : National Cancer Institute

---

Locations

Canada, Alberta

Canada, Manitoba

Canada, Newfoundland and Labrador

Canada, Nova Scotia

Canada, Ontario

Canada, Saskatchewan